Mineralys Therapeutics (MLYS) Non Operating Income (2022 - 2026)

Mineralys Therapeutics has disclosed Non Operating Income across 5 years of filings, most recently posting $6.0 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $6.0 million, up 168.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.7 million (up 353.81% YoY), and the FY2024 annual result was $5000.0, down 99.96% from the prior year.
• Non Operating Income came in at $6.0 million for Q1 2026 at Mineralys Therapeutics, up from $1000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $6.0 million in Q1 2026 to a low of -$11.8 million in Q4 2024.
• The 5-year median for Non Operating Income is $2.8 million (2023), against an average of $1.6 million.
• Across the five-year window, Non Operating Income tumbled 454.21% in 2024 and surged 42090.0% in 2025, its largest moves.
• Mineralys Therapeutics' Non Operating Income stood at $935000.0 in 2022, then jumped by 255.29% to $3.3 million in 2023, then sank by 454.21% to -$11.8 million in 2024, then soared by 100.01% to $1000.0 in 2025, then surged by 600000.0% to $6.0 million in 2026.
• The last three Non Operating Income figures came in at $6.0 million (Q1 2026), $1000.0 (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.